Particle Sciences will have commercial manufacturing capabilities operating at its Pennsylvania facility by the end of the year and will add 30 jobs.
Japan’s Sawai is following other drugmakers by establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation.
Thermo Fisher Scientific is acquiring Patheon—the center of the consolidation that has swept through contract manufacturing—in a deal valued at $7.2 billion.
The Teva divestment rumors are true. The company wants to sell off its women’s health and European oncology and pain businesses to pay down debt.
Anyone who tuned into Allergan’s Q1 earnings call hoping for signs of big M&A to come likely left disappointed.
Is Pfizer thinking of buying Bristol-Myers Squibb, as the rumors go? CEO Ian Read hinted at the possibility on Tuesday's Q1 earnings call.
Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.
Swedish CDMO Recipharm’s growing global footprint in 2016 has positioned the company to take advantage of what is expected to be more consolidation and growth…
Growth in the generic sterile manufacturing industry has spawned a series of big buyouts in the last few years, and Germany’s Fresenius is looking to M&A…
London-based private equity firm Permira is buying out Lyophilization Services of New England (LSNE).